Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (8408)	1/30/2006 5:14:49 AM
From: Galirayo	Read Replies (1) \| Respond to of 23958

[AMLN] Up Date .. Looks like a Negative Barrons Spin. stockcharts.com Investors should be cautious on Amylin - Barron's Sun Jan 29, 2006 05:11 PM ET NEW YORK, Jan 29 (Reuters) - Investors in Amylin Pharmaceuticals Inc. (AMLN.O: Quote, Profile, Research) should be cautious, as most of the good news about its star diabetes drug Byetta appears to be fully priced into the expensive stock, financial weekly Barron's reported. Amylin's stock market value already exceeds $4.8 billion, or 37 times its expected 2005 sales, and much hinges on it getting U.S. approval for a once-a-week version of Byetta, Barron's said. But regulatory delays could hurt the company, while endocrinologists at cancer centers in New York and Texas say they wish there had been research into Byetta's effect on human thyroid tissue called C-cells, Barron's said. Still, the cancer specialists said the risk-benefit balance strongly favors Byetta, Barron's said. © Reuters 2006. All Rights Reserved. yahoo.reuters.com